Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial

IMPORTANCE: Current treatments for long-term prophylaxis in hereditary angioedema have limitations. OBJECTIVE: To assess the efficacy of lanadelumab, a fully human monoclonal antibody that selectively inhibits active plasma kallikrein, in preventing hereditary angioedema attacks. DESIGN, SETTING, AN...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JAMA
Main Authors: Banerji, Aleena, Riedl, Marc A., Bernstein, Jonathan A., Cicardi, Marco, Longhurst, Hilary J., Zuraw, Bruce L., Busse, Paula J., Anderson, John, Magerl, Markus, Martinez-Saguer, Inmaculada, Davis-Lorton, Mark, Zanichelli, Andrea, Li, H. Henry, Craig, Timothy, Jacobs, Joshua, Johnston, Douglas T., Shapiro, Ralph, Yang, William H., Lumry, William R., Manning, Michael E., Schwartz, Lawrence B., Shennak, Mustafa, Soteres, Daniel, Zaragoza-Urdaz, Rafael H., Gierer, Selina, Smith, Andrew M., Tachdjian, Raffi, Wedner, H. James, Hebert, Jacques, Rehman, Syed M., Staubach, Petra, Schranz, Jennifer, Baptista, Jovanna, Nothaft, Wolfram, Maurer, Marcus
פורמט: Artigo
שפה:Inglês
יצא לאור: American Medical Association 2018
נושאים:
Original Investigation
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6583584/
https://ncbi.nlm.nih.gov/pubmed/30480729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2018.16773
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים